{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(5)"],"submitter":["Kim SH"],"pubmed_abstract":["<h4>Importance</h4>Chronic kidney disease (CKD) is a significant risk factor for both ischemic and bleeding complications following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Optimizing dual antiplatelet therapy (DAPT) is essential for improving clinical outcomes.<h4>Objective</h4>To evaluate whether an 11-month, unguided deescalation strategy from ticagrelor to clopidogrel was associated with reduced bleeding without an increase in ischemic events in stabilized patients with CKD after AMI.<h4>Design, setting, and participants</h4>This was a post hoc secondary analysis of the multicenter, open-label, Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial conducted at 32 major cardiac cente"],"journal":["JAMA network open"],"pagination":["e2511297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12093190"],"repository":["biostudies-literature"],"pubmed_title":["Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial."],"pmcid":["PMC12093190"],"pubmed_authors":["Her SH","TALOS-AMI Investigators","Kim SW","Lim S","Yoon MH","Choi IJ","Lee M","Huh SH","Park KM","Jang JS","Lee KY","Kim KS","Oh JH","Kim CJ","Byeon J","Kim SH","Sung KC","Cho JM","Park SH","Lee JH","Do JH","Chang K","Cho YH","Hwang BH","Cho BR","Lee SH","Baek JY","Jung SS","Park JS","Park MW","Kim W","Shin WS","Choo EH","Park CS","Ko JS","Cha KS","Shim BJ","Sa YK","Kim DB","Cho CH","Chung KT","Jeong MH","Choi YS"],"additional_accession":[]},"is_claimable":false,"name":"Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial.","description":"<h4>Importance</h4>Chronic kidney disease (CKD) is a significant risk factor for both ischemic and bleeding complications following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Optimizing dual antiplatelet therapy (DAPT) is essential for improving clinical outcomes.<h4>Objective</h4>To evaluate whether an 11-month, unguided deescalation strategy from ticagrelor to clopidogrel was associated with reduced bleeding without an increase in ischemic events in stabilized patients with CKD after AMI.<h4>Design, setting, and participants</h4>This was a post hoc secondary analysis of the multicenter, open-label, Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial conducted at 32 major cardiac cente","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T10:22:31.288Z","creation":"2026-04-08T11:23:21.772Z"},"accession":"S-EPMC12093190","cross_references":{"pubmed":["40392554"],"doi":["10.1001/jamanetworkopen.2025.11297"]}}